Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325160 | 0.84 | TAAR1 (0.61) | TAAR1HTR2AAOC3CHRM2ADRA1A | |
| SCHEMBL28511682 | 0.80 | TAAR1 (0.52) | TAAR1HTR2AAOC3CHRM2ADRA1A | |
| SCHEMBL6547351 | 0.79 | HKDC1 (0.52) | TAAR1AOC3CHRM2ADRA1ACYP3A4 | |
| SCHEMBL28411588 | 0.78 | TAAR1 (0.45) | TAAR1AOC3CHRM2ADRA1AHSD17B10 | |
| SCHEMBL4695342 | 0.77 | TAAR1 (0.72) | TAAR1HTR2AAOC3CYP3A4CYP2D6 | |
| SCHEMBL11478651 | 0.77 | HKDC1 (0.55) | TAAR1HTR2AAOC3CHRM2ADRA1A | |
| SCHEMBL2220321 | 0.77 | TAAR1 (0.48) | TAAR1HTR2AAOC3CHRM2ADRA1A | |
| SCHEMBL4820239 | 0.76 | TAAR1 (0.41) | TAAR1HTR2ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9747206 | 0.76 | TAAR1 (0.50) | TAAR1HTR2AADRA1ACYP2D6ADRA2C | |
| SCHEMBL2464535 | 0.76 | TAAR1 (0.47) | TAAR1HTR2AAOC3CHRM2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043689-B2 | Nickel catalysts with single metal cations for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043688-B2 | Nickel catalysts with two alkali ions for homopolymerization and copolymerization | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4374928-A2 | NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING | The Brigham And Women's Hospital Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166775-A1 | NICKEL CATALYSTS WITH TWO METAL CATIONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024097972-A2 | COMPOUNDS AND METHODS FOR TREATING CANCERS | CEDARS-SINAI MEDICAL CENTER (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3484474-B1 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | CHILDRENS MEDICAL CT CORP (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240117076-A1 | NICKEL CATALYSTS WITH SINGLE METAL CATIONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-04-11 | — | — | US | disclosed |
| US-11944625-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240101727-A1 | NICKEL CATALYSTS WITH TWO ALKALI IONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240101726-A1 | NICKEL CATALYSTS WITH SINGLE ALKALI IONS FOR HOMOPOLYMERIZATION AND COPOLYMERIZATION | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001019808-A1 | CHEMICAL COMPOUNDS AND COMPOSITIONS AND THEIR USE AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944625-B2 | Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | RPS6KA1, RPS6KA2, RPS6KA6 | TAAR1 4581/4885HTR2A 2778/4885AOC3 4838/4885 |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP14, CASP4 | TAAR1 3812/4885HTR2A 3536/4885AOC3 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.